Shu, Liqi; Bakradze, Ekaterina; Omran, Setareh Salehi; Giles, James; Amar, Jordan; Henninger, Nils; Elnazeir, Marwa; Liberman, Ava; Moncrieffe, Khadean; Rotblat, Jenny; Sharma, Richa; Cheng, Yee; Zubair, Adeel S; Simpkins, Alexis; Li, Grace; Kung, Justin; Perez, Dezaray; Heldner, Mirjam R; Scutelnic, Adrian; von Martial, Rascha; ... (2022). Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study. Neurology, 99(21), e2368-e2377. Lippincott Williams & Wilkins 10.1212/WNL.0000000000201122
|
Text
WNL.0000000000201122.full.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
BACKGROUND
and Purpose: Cerebral venous thrombosis (CVT) is a rare cause of stroke carrying a nearly 4% risk of recurrence after 1 year. There is limited data on predictors of recurrent venous thrombosis in patients with CVT. In this study, we aim to identify those predictors.
METHODS
This is a secondary analysis of the ACTION-CVT study which is a multi-center international study of consecutive patients hospitalized with a diagnosis of CVT over a 6-year period. Patients with cancer associated CVT, CVT during pregnancy, or CVT in the setting of known antiphospholipid antibody syndrome were excluded per the ACTION-CVT protocol. The study outcome was recurrent venous thrombosis defined as recurrent venous thromboembolism (VTE) or de-novo CVT. We compared characteristics between patients with vs. without recurrent venous thrombosis during follow-up and performed adjusted Cox regression analyses to determine important predictors of recurrent venous thrombosis.
RESULTS
947 patients were included with a mean age was 45.2 years, 63.9% were women, and 83.6% had at least 3-months of follow-up. During a median follow-up of 308 (IQR 120-700) days, there were 5.05 recurrent venous thromboses (37 VTE and 24 de-novo CVT) per 100 patient-years. Predictors of recurrent venous thrombosis were Black race (adjusted HR 2.13, 95% CI 1.14-3.98, p = 0.018), prior history of VTE (aHR 3.40, 95% CI 1.80-6.42, p < 0.001) and the presence of one or more positive antiphospholipid antibodies (aHR 3.85, 95% CI 1.97-7.50, p < 0.001). Sensitivity analyses including events only occurring on oral anticoagulation yielded similar findings.
CONCLUSION
Black race, history of VTE, and the presence of one or more antiphospholipid antibodies are associated with recurrent venous thrombosis among patients with CVT. Future studies are needed to validate our findings to better understand mechanisms and treatment strategies in patients with CVT.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Heldner, Mirjam Rachel, Scutelnic, Adrian, von Martial, Rascha, Siepen, Bernhard Matthias |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
0028-3878 |
Publisher: |
Lippincott Williams & Wilkins |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
21 Sep 2022 14:08 |
Last Modified: |
20 Sep 2023 00:25 |
Publisher DOI: |
10.1212/WNL.0000000000201122 |
PubMed ID: |
36123126 |
BORIS DOI: |
10.48350/173106 |
URI: |
https://boris.unibe.ch/id/eprint/173106 |